FITC anti-mouse CD3 Antibody

Pricing & Availability
Clone
17A2 (See other available formats)
Regulatory Status
RUO
Other Names
T cell antigen receptor complex, T3
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
17A2
C57BL/6 splenocytes stained with 17A2 FITC and 145-2C11 PE
  • 17A2
    C57BL/6 splenocytes stained with 17A2 FITC and 145-2C11 PE
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100203 50 µg $36
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100204 500 µg $143
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3, also known as T3, is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3 is composed of CD3ε, δ, γ and ζ chains. It forms a TCR complex by associating with TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
γδTCR-positive T-T hybridoma D1
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported application (for relevant formats) include: spatial biology (IBEX)1,2.

Application References

(PubMed link indicates BioLegend citation)
  1. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  2. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  2. Jiang W, et al. 2017. Sci Rep. 7:6501. PubMed
  3. Petrova T, et al. 2020. Sci Rep. 10:3479. PubMed
  4. Zhang H, et al. 2021. Front Immunol. 12:644520. PubMed
  5. Garo LP, et al. 2021. Nat Commun. 12:2419. PubMed
  6. Lee JH, et al. 2022. EBioMedicine. 77:103903. PubMed
  7. Zhu Y, et al. 2022. Nat Commun. 13:4282. PubMed
  8. Harel M, et al. 2020. J Immunol. 205:1167. PubMed
  9. Bruno MEC, et al. 2022. J Cell Physiol. 237:706. PubMed
  10. Pei J, et al. 2022. J Virol. 96:e0194221. PubMed
  11. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  12. Meng J, et al. 2022. Cell Rep. 38:110492. PubMed
  13. Corral D, et al. 2022. Cell Rep. 39:110715. PubMed
  14. Yue Y, et al. 2022. Nat Biomed Eng. 6:898. PubMed
  15. Brog RA, et al. 2022. Cancer Immunol Res. 10:962. PubMed
  16. Wu J, et al. 2023. Bioact Mater. 20:259. PubMed
  17. Shen CY, et al. 2022. Pharmaceutics. 14: . PubMed
  18. Brigo N, et al. 2022. Bio Protoc. 12:e4440. PubMed
  19. Hong Y, et al. 2022. J Leukoc Biol. 112:425. PubMed
  20. Mugarza E, et al. 2022. Sci Adv. 8:eabm8780. PubMed
  21. Xie DH, et al. 2022. Med Phys. 49:6728. PubMed
  22. Gong F, et al. 2023. Adv Healthc Mater. 12:e2201771. PubMed
  23. Gao Y, et al. 2022. Cell Res. 32:1086. PubMed
  24. Chen Y, et al. 2023. Adv Healthc Mater. 12:e2202085. PubMed
  25. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  26. Liang Y, et al. 2022. Theranostics. 12:7729. PubMed
  27. You Q, et al. 2023. Adv Mater. 35:e2204910. PubMed
  28. Kim HI, et al. 2022. Molecules. 27: . PubMed
  29. Shi C, et al. 2023. Nat Nanotechnol. 18:86. PubMed
  30. Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed
  31. Yu J, et al. 2022. Nat Commun. 13:7903. PubMed
  32. Schepers M, et al. 2023. Brain Behav Immun. 109:1. PubMed
  33. Ding L, et al. 2023. J Clin Invest. 133: . PubMed
  34. Peng Q, et al. 2023. EMBO Rep. 24:e56034. PubMed
  35. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  36. Liu H, et al. 2023. Cell Death Differ. :. PubMed
  37. Tsioti I, et al. 2023. J Neuroinflammation. 20:25. PubMed
  38. Gon Y, et al. 2023. PLoS One. 18:e0279389. PubMed
  39. Wang L, et al. 2023. Oxid Med Cell Longev. 2023:6480848. PubMed
  40. Zhang W, et al. 2022. Dev Cell. 57:329. PubMed
  41. Meacham CE, et al. 2022. Nat Cell Biol. 24:697. PubMed
  42. Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed
  43. Bruggemann TR, et al. 2022. iScience. 25:105185. PubMed
  44. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  45. Dai L, et al. 2020. Cell. 182(3):722-733.e11. PubMed
  46. Xing J, et al. 2021. Cell Reports. 35(12):109205. PubMed
  47. Zaman R, et al. 2021. Immunity. :. PubMed
  48. Zimmerman SM, et al. 2022. Oncogene. 41:4983. PubMed
  49. Peng J, et al. 2023. Am J Reprod Immunol. 89:e13678. PubMed
  50. Chen H, et al. 2023. Nat Commun. 14:941. PubMed
  51. Wang F, et al. 2023. Int J Mol Sci. 24:. PubMed
  52. Liu HJ, et al. 2023. Nat Commun. 14:1214. PubMed
  53. Guo D, et al. 2023. Cell Biosci. 13:51. PubMed
  54. Dang YZ, et al. 2023. Neoplasma. 70:123. PubMed
  55. Wang Y, et al. 2023. Front Bioeng Biotechnol. 11:1128268. PubMed
  56. Sambandam A, et al. 2023. Heliyon. 9:e14238. PubMed
  57. Masle-Farquhar E, et al. 2023. Front Immunol. 14:1095257. PubMed
  58. Tao Q, et al. 2023. Microbiol Spectr. :e0522922. PubMed
  59. Tan X, et al. 2023. Adv Sci (Weinh). 10:e2206768. PubMed
  60. Zhang YN, et al. 2023. Nat Commun. 14:1985. PubMed
  61. Ito M, et al. 2023. Sci Rep. 13:5939. PubMed
  62. Huang T, et al. 2023. Front Immunol. 14:1124152. PubMed
  63. Kuang C, et al. 2023. Nat Commun. 14:2093. PubMed
  64. Zuo B, et al. 2023. Clin Transl Oncol. . PubMed
  65. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  66. Wang K, et al. 2023. Nat Commun. 14:2950. PubMed
  67. Wang D, et al. 2023. Nat Commun. 14:2943. PubMed
  68. Xie J, et al. 2023. Mol Ther Oncolytics. 29:61. PubMed
  69. Feng X, et al. 2023. Nat Commun. 14:3208. PubMed
  70. Zeng S, et al. 2023. Front Oncol. 13:1171926. PubMed
  71. Lan Y, et al. 2023. iScience. 26:106817. PubMed
  72. Yang QC, et al. 2023. iScience. 26:106916. PubMed
  73. Lin W, et al. 2020. Theranostics. 10:4871. PubMed
  74. Gawish R, et al. 2022. Elife. 11:. PubMed
  75. Qiao Y, et al. 2021. Oncoimmunology. 10:1947569. PubMed
  76. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  77. Manukian G, et al. 2021. Int J Radiat Oncol Biol Phys. 110:1341. PubMed
  78. Jiang Q, et al. 2022. Theranostics. 12:59. PubMed
  79. Wilhelm J, et al. 2021. J Control Release. 329:353. PubMed
  80. Ford K, et al. 2020. Cancer Res. 80:1846. PubMed
  81. Delvecchio FR, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1543. PubMed
  82. Zhang R, et al. 2021. Cell Mol Immunol. 18:1222. PubMed
  83. Tang L, et al. 2021. Oncol Lett. 22:605. PubMed
  84. Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed
  85. Miller CM, et al. 2020. J Virol. 94:00:00. PubMed
  86. Boyd DF, et al. 2020. Nature. 587:466. PubMed
  87. Wu X, et al. 2012. Biochem Pharmacol. 84:1164. PubMed
  88. Du Q, et al. 2019. Front Microbiol. 10:2050. PubMed
  89. Song C, et al. 2019. Nat Commun. 10:3745. PubMed
  90. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  91. Chou YJ, et al. 2020. Sci Rep. 10:8422. PubMed
  92. Bromley SK, et al. 2020. Cell Reports. 32(9):108085. PubMed
  93. Turner JA, et al. 2020. Immunity. 53:1202. PubMed
  94. Jiang W, et al. 2021. Oncol Lett. 22:625. PubMed
  95. Choi YY, et al. 2021. Cell Death Dis. 12:826. PubMed
  96. Almeida AS, et al. 2021. Bio Protoc. 11:e4012. PubMed
  97. Zhang S, et al. 2022. Acta Pharm Sin B. 12:3124. PubMed
  98. Steubing RD, et al. 2022. Brain Behav Immun Health. 24:100493. PubMed
  99. Mei S, et al. 2022. Front Immunol. 13:911164. PubMed
  100. Lu H, et al. 2021. Autophagy. 17:2511. PubMed
  101. Bao H, et al. 2020. Mol Med Rep. 4.675. PubMed
  102. Sun CC, et al. 2020. Genome Med. 0.553472222. PubMed
  103. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
  104. Diao L, et al. 2022. iScience. 25:105511. PubMed
  105. Bangs DJ, et al. 2022. Cell Rep. 38:110266. PubMed
  106. Huang Y, et al. 2021. Radiother Oncol. 162:34. PubMed
  107. Zhao J, et al. 2022. J Nanobiotechnology. 20:62. PubMed
  108. Ren J, et al. 2021. Theranostics. 11:304. PubMed
  109. Tan X, et al. 2021. Front Oncol. 11:768222. PubMed
  110. Oliva Chávez AS, et al. 2021. Nat Commun. 12:3696. PubMed
  111. Liu Q, et al. 2021. Cell Death Dis. 12:240. PubMed
  112. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  113. Antonia O Cuff et al. 2017. Wellcome open research. 2:39 . PubMed
  114. Davis FM, et al. 2019. Arterioscler Thromb Vasc Biol. 39:2353. PubMed
  115. Pham THM, et al. 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed
  116. Lesmeister M, et al. 2005. Reprod Biol Endocrinol. 29:74. PubMed
  117. Dolgova EV, et al. 2022. Int J Mol Sci. 23:. PubMed
  118. Mostafavi H, et al. 2022. PLoS Pathog. 18:e1010185. PubMed
  119. Sala D, et al. 2022. Mol Ther Methods Clin Dev. 25:170. PubMed
  120. Starkl P, et al. 2020. Immunity. 53(4):793-804.e9. PubMed
  121. Ning X, et al. 2019. Mol Cell. 74:19. PubMed
  122. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  123. Deng P, et al. 2022. Cells. 11:. PubMed
  124. Li Y, et al. 2022. Clin Transl Immunology. 11:e1362. PubMed
  125. Zhan Y, et al. 2021. JCI Insight. 6:. PubMed
  126. Yu AI, et al. 2020. Cell Rep. 107471:31. PubMed
  127. Jiang S, et al. 2020. Scand J Immunol. e12867:91. PubMed
  128. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  129. White C, et al. 2014. J Immunol. 193:5933. PubMed
  130. Chen Y, et al. 2012. PLoS One. 7:e47190. PubMed
  131. Solanki A, et al. 2018. Development. 145. PubMed
  132. Shields BD, et al. 2019. Cancer Res. 79:1113. PubMed
  133. Dang Y, et al. 2022. Cancer Cell Int. 22:88. PubMed
  134. Almeida AS, et al. 2021. Bio Protoc. 11:e4012. PubMed
  135. Geng T, et al. 2022. Methods Mol Biol. 2585:71. PubMed
  136. Lee M, et al. 2014. PLoS One. 9:112666. PubMed
  137. Mingozzi F, et al. 2016. EMBO Mol Med. 8: 1039 - 1051. PubMed
  138. Park HB, et al. 2020. Oncoimmunology. 9:1772663. PubMed
  139. Kimball AS et al. 2019. Immunity. 51(2):258-271 . PubMed
  140. Naing A et al. 2019. Cell reports. 26(5):1242-1257 . PubMed
  141. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  142. Carr RM, et al. 2021. Nat Commun. 12:2901. PubMed
  143. Pervaiz N, et al. 2021. Pigment Cell Melanoma Res. 34:918. PubMed
  144. Sun Y, et al. 2022. Nat Commun. 13:3916. PubMed
  145. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  146. Wang X, et al. 2018. Mol Med Rep. 17:1660. PubMed
  147. Lee JS et al. 2018. Cell. 174(6):1559-1570 . PubMed
  148. Comazzetto S et al. 2018. Cell stem cell. 24(3):477-486 . PubMed
  149. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  150. Hanasoge Somasundara AV, et al. 2021. Cell Rep. 37:110099. PubMed
  151. Shi R, et al. 2022. Theranostics. 12:875. PubMed
  152. Jie X, et al. 2022. J Immunother Cancer. 10:. PubMed
  153. Chen Q, et al. 2016. Nat Commun. 7:13193. PubMed
  154. Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
  155. Li Y, et al. 2020. Cell Stem Cell. 27(5):732-747.e7. PubMed
  156. Omori S, et al. 2021. Cell Reports. 34(6):108734. PubMed
  157. Sreekumar PG, et al. 2018. J Control Release. 283:94. PubMed
  158. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  159. Li W, et al. 2019. Nat Commun. 10:3349. PubMed
  160. Xu X, et al. 2018. Cell. 175:1336. PubMed
  161. Reismann D, et al. 2017. Nat Commun.. 10.1038/s41467-017-01538-9. PubMed
  162. Ishidome T et al. 2017. EBioMedicine. 22:89-99 . PubMed
  163. Ding Y, et al. 2022. Cell Death Dis. 13:996. PubMed
  164. Tang X, et al. 2022. Cell Rep. 41:111673. PubMed
  165. Wei W, et al. 2022. mSystems. 7:e0046922. PubMed
  166. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  167. Zhou H, et al. 2022. Oncoimmunology. 11:2057892. PubMed
  168. Yang J, et al. 2022. Microbiome. 10:149. PubMed
  169. Harnett MM, et al. 2022. Front Immunol. 13:953053. PubMed
  170. Koren E, et al. 2022. Nat Commun. 13:4628. PubMed
  171. Zhang C, et al. 2022. Nat Commun. 13:3468. PubMed
  172. Chen X, et al. 2021. Cell Rep. 37:109991. PubMed
  173. Ye P, et al. 2022. Front Cardiovasc Med. 8:810477. PubMed
  174. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  175. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  176. Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed
  177. Tacconi C, et al. 2021. Cell Reports. 35(2):108993. PubMed
  178. Elahi S, et al. 2020. Stem Cell Res. 43:101710. PubMed
  179. Akhter N, et al. 2016. J Biol Chem. 291: 23672 - 23680. PubMed
  180. Huang B, et al. 2015. PLoS One. 10: 0134715. PubMed
  181. Markey K, et al. 2014. J Immunol. 192:5426. PubMed
  182. Moon HG et al. 2018. Immunity. 49(2):275-287 . PubMed
  183. Ren W, et al. 2018. Mucosal Immunol. 12:531. PubMed
  184. Liu W, et al. 2021. Cell Death Discov. 7:136. PubMed
  185. França TT, et al. 2021. JCI Insight. 6:. PubMed
  186. Carbone C, et al. 2021. J Immunother Cancer. 9:. PubMed
  187. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  188. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  189. Du J, et al. 2012. Stem Cells. 30:1447. PubMed
  190. Weinheimer-Haus E, et al. 2014. PLoS One. 9:91355. PubMed
  191. Zheng L, et al. 2020. Front Oncol. 10:531131. PubMed
  192. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  193. Choi EW, et al. 2020. Sci Rep. 10:12001. PubMed
  194. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  195. Cohen M et al. 2018. Cell. 175(4):1031-1044 . PubMed
  196. Ma W, et al. 2017. Cell Death & Disease. 10.1038/cddis.2017.47. PubMed
  197. Yang Z, et al. 2021. Onco Targets Ther. 14:4239. PubMed
  198. Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
  199. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  200. Port JR, et al. 2020. J Virol. 94:. PubMed
  201. Rashid MH, et al. 2021. Oncol Rep. 45:1171. PubMed
  202. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  203. Alsina-Sanchis E, et al. 2020. Mol Cancer Res. . PubMed
  204. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  205. Zhang W, et al. 2019. Mar Drugs. 0.845138889. PubMed
  206. Nowlan B, et al. 2019. Haematologica. 105:71. PubMed
  207. Zhang W, et al. 2020. Nat Commun. 11:1187. PubMed
  208. Yu H, et al. 2021. Front Oncol. 11:736882. PubMed
  209. Xiao Y, et al. 2022. Nat Commun. 13:758. PubMed
  210. Zhang R, et al. 2022. Front Pharmacol. 13:870848. PubMed
  211. Ali S, et al. 2021. PLoS One. 16:e0246646. PubMed
  212. Yang Z, et al. 2021. Nat Commun. 12:4852. PubMed
  213. Pandit M, et al. 2021. Eur J Immunol. 51:1461. PubMed
  214. Lingegowda H, et al. 2022. Front Reprod Health. 3:726936. PubMed
  215. He J, et al. 2020. Evid Based Complement Alternat Med. 2020:5637507. PubMed
  216. Roy S, et al. 2019. Front Immunol. 2.404166667. PubMed
  217. Scally S, et al. 2017. Nat Commun. . 10.1038/s41467-017-01924-3. PubMed
  218. Yi H, et al. 2021. Front Immunol. 12:719189. PubMed
  219. Qi J, et al. 2021. Nat Commun. 12:4755. PubMed
  220. Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
  221. Zhang YN, et al. 2021. Sci Adv. 7:eabj3107. PubMed
  222. Murdock BJ, et al. 2021. JCI Insight. 6:. PubMed
  223. Robertson TF, et al. 2021. J Cell Biol. 220:. PubMed
  224. Mohammadi MR, et al. 2021. Commun Biol. 4:685. PubMed
  225. Li X, et al. 2021. Cell Death Dis. 12:314. PubMed
  226. Wang Z, et al. 2021. Acta Pharm Sin B. 694:11. PubMed
  227. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  228. Wu L, et al. 2020. Cell Rep. 33:108327. PubMed
  229. Zan H, et al. 2017. Nat Commun. 8:14244. PubMed
  230. Cabrera-Perez J, et al. 2016. J Immunol. 197: 1692 - 1698. PubMed
  231. Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed
  232. Cabrera-Perez C, et al. 2015. J Immunol . 194:1609-20. PubMed
  233. Chen X, et al. 2019. Med Sci Monit. 25:5389. PubMed
  234. Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed
  235. Smith-Díaz CC, et al. 2021. Front Oncol. 11:709543. PubMed
  236. Tsai HI, et al. 2021. EMBO Mol Med. 13:e12834. PubMed
  237. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  238. Lai Y, et al. 2022. Clin Transl Med. 12:e999. PubMed
  239. Zhang J, et al. 2022. Biomater Res. 26:44. PubMed
  240. Li M, et al. 2021. Br J Pharmacol. 178:2617. PubMed
  241. Yang YS, et al. 2022. Nat Commun. 13:6175. PubMed
  242. Baumann D, et al. 2020. Nat Commun. 1.969444444. PubMed
  243. Chen C, et al. 2020. Front Cell Neurosci. 14:8. PubMed
  244. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  245. Chen Y, et al. 2022. Nat Commun. 13:4468. PubMed
  246. Nam J, et al. 2021. Adv Ther (Weinh). 4:. PubMed
  247. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  248. Zhou H, et al. 2021. Cell Death Discov. 7:332. PubMed
  249. Yang Z, et al. 2021. Nat Commun. 12:4299. PubMed
  250. van den Berk P, et al. 2020. Cell Rep. 33:108533. PubMed
  251. Harb H, et al. 2020. Nat Immunol. 1359:21. PubMed
  252. Campolo M, et al. 2020. Int J Mol Sci. 21:00. PubMed
  253. Jia H, et al. 2018. Int J Oncol. 53:949. PubMed
  254. Chao Y, et al. 2020. Sci Adv. 6:eaaz4204. PubMed
  255. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  256. Magee JA, et al. 2021. Stem Cell Reports. 16:20. PubMed
  257. Fujimoto M, et al. 2022. Nat Commun. 13:5408. PubMed
  258. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  259. Ravindran Menon D, et al. 2021. Pharmaceuticals (Basel). 14:. PubMed
  260. Le QV, et al. 2022. Bioact Mater. 15:160. PubMed
  261. Aulova KS, et al. 2022. Molecules. 27:. PubMed
  262. Yang N, et al. 2022. Nat Commun. 13:2336. PubMed
  263. Xu Y, et al. 2016. Nat Commun. 7:12073. PubMed
  264. Zheng DW, et al. 2020. Nat Commun. 3.865972222. PubMed
  265. Pan X, et al. 2019. BMC Complement Altern Med. 19:163. PubMed
  266. Li K, et al. 2020. Nat Commun. 0.795138889. PubMed
  267. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  268. Zukauskas A, et al. 2018. mSphere. 3:e00303. PubMed
  269. Tao Z, et al. 2022. Cells. 11:. PubMed
  270. Tang T, et al. 2022. J Immunother Cancer. 10:. PubMed
  271. Zhou Y, et al. 2022. Theranostics. 12:5488. PubMed
  272. Chen LH, et al. 2021. Sci Rep. 11:19478. PubMed
  273. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  274. Wang J, et al. 2021. Am J Cancer Res. 11:2005. PubMed
  275. Wang F, et al. 2021. Neoplasia. 23:281. PubMed
  276. Guo X, et al. 2020. J Cell Mol Med. . PubMed
  277. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  278. Yu H, et al. 2015. PLoS One. 10: 0143001. PubMed
  279. Tanegashima K et al. 2017. EBioMedicine. 24:247-256 . PubMed
  280. Crowe J, et al. 2020. PLoS Pathog. 16:e1008391. PubMed
  281. Tur J, et al. 2020. Cell Reports. 32(8):108079. PubMed
  282. Mincham KT, et al. 2021. Front Immunol. 11:601494. PubMed
  283. Zheng Y, et al. 2022. Transl Res. :. PubMed
  284. Gawish R, et al. 2022. Elife. 11:. PubMed
  285. Li J, et al. 2022. Nat Commun. 13:1481. PubMed
  286. Roberto MP, et al. 2021. Immunity. 54(8):1807-1824.e14. PubMed
  287. Goldberg EL, et al. 2021. Cell Metabolism. :. PubMed
  288. Martínez-Vicente P, et al. 2019. PLoS Pathog. 15:e1007658. PubMed
  289. Liu WL, et al. 2019. Nat Commun. 10:3199. PubMed
  290. Kubli SP, et al. 2019. Nat Commun. 10:2678. PubMed
  291. Sun Q, et al. 2022. J Inflamm Res. 15:5827. PubMed
  292. Cao Y, et al. 2022. Small. 18:e2203466. PubMed
  293. Li C, et al. 2022. Front Cell Dev Biol. 10:913824. PubMed
  294. Xu Z, et al. 2022. Cell Death Dis. 13:502. PubMed
  295. Pastor Arroyo EM, et al. 2022. Clin Sci (Lond). 136:557. PubMed
  296. Erens C, et al. 2022. Biomedicines. 10:. PubMed
  297. Zhang J, et al. 2021. Stem Cell Res Ther. 12:579. PubMed
  298. Gu Z, et al. 2021. Nat Genet. 53:672. PubMed
  299. Zuo S, et al. 2021. EBioMedicine. 64:103240. PubMed
  300. Zheng QY, et al. 2020. FASEB J. 34:10590. PubMed
  301. Li J, et al. 2021. eLife. 10:00. PubMed
  302. Trivedi S, et al. 2020. Elife. 9:00. PubMed
  303. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
  304. Fan X, et al. 2014. PLoS One. 9:107638. PubMed
RRID
AB_312661 (BioLegend Cat. No. 100203)
AB_312661 (BioLegend Cat. No. 100204)

Antigen Details

Structure
Ig superfamily, CD3/TCR, 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
Antigen recognition, TCR signal transduction, T cell activation
Ligand/Receptor
Peptide antigen/MHC-complex
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12502 View all products for this Gene ID
UniProt
View information about CD3 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD3 Reagents Request Custom Conjugation
Description Clone Applications
FITC anti-mouse CD3 17A2 FC
PE anti-mouse CD3 17A2 FC
Purified anti-mouse CD3 17A2 FC,IHC-F,IP,ICC
Alexa Fluor® 647 anti-mouse CD3 17A2 FC,IHC-F,3D IHC,SB
Alexa Fluor® 488 anti-mouse CD3 17A2 FC,IHC-F,3D IHC
Pacific Blue™ anti-mouse CD3 17A2 FC
Alexa Fluor® 700 anti-mouse CD3 17A2 FC
PerCP/Cyanine5.5 anti-mouse CD3 17A2 FC
PE/Cyanine7 anti-mouse CD3 17A2 FC
APC/Cyanine7 anti-mouse CD3 17A2 FC
Brilliant Violet 421™ anti-mouse CD3 17A2 FC,ICC
Brilliant Violet 570™ anti-mouse CD3 17A2 FC
Brilliant Violet 650™ anti-mouse CD3 17A2 FC
Brilliant Violet 785™ anti-mouse CD3 17A2 FC
Brilliant Violet 510™ anti-mouse CD3 17A2 FC
APC anti-mouse CD3 17A2 FC
Ultra-LEAF™ Purified anti-mouse CD3 17A2 FC,IHC-F,IP,ICC
Brilliant Violet 605™ anti-mouse CD3 17A2 FC
Alexa Fluor® 594 anti-mouse CD3 17A2 IHC-F,FC,3D IHC,SB
Brilliant Violet 711™ anti-mouse CD3 17A2 FC
Biotin anti-mouse CD3 17A2 FC,IHC-F
PE/Dazzle™ 594 anti-mouse CD3 17A2 FC
APC/Fire™ 750 anti-mouse CD3 17A2 FC
Brilliant Violet 750™ anti-mouse CD3 17A2 FC
TotalSeq™-A0182 anti-mouse CD3 17A2 PG
TotalSeq™-B0182 anti-mouse CD3 17A2 PG
Spark Blue™ 550 anti-mouse CD3 17A2 FC
Spark NIR™ 685 anti-mouse CD3 17A2 FC
TotalSeq™-C0182 anti-mouse CD3 17A2 PG
APC/Fire™ 810 anti-mouse CD3 17A2 FC
PE/Fire™ 640 anti-mouse CD3 17A2 FC
Spark YG™ 570 anti-mouse CD3 17A2 IHC-F
PE/Fire™ 700 anti-mouse CD3 17A2 FC
PE/Cyanine5 anti-mouse CD3 17A2 FC
Spark Blue™ 574 anti-mouse CD3 Antibody 17A2 FC
Spark Violet™ 423 anti-mouse CD3 17A2 FC
PE/Fire™ 810 anti-mouse CD3 17A2 FC
Spark Red™ 718 anti-mouse CD3 17A2 FC
Spark UV™ 387 anti-mouse CD3 17A2 FC
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login/Register
Remember me
Forgot your password? Reset Password
Request an Account